AGM on July 25, 2014
Glenmark Pharmaceuticals Ltd has informed BSE that the 36th Annual General Meeting (AGM) of the Company will be held on July 25, 2014.11-07-2014
11-07-2014
Glenmark Generics receives final ANDA approval for Telmisartan Tablets
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated July 08, 2014 titled "Glenmark Generics receives final ANDA approval for Telmisartan Tablets"08-07-2014
Shareholding Pattern For June 30, 2014
Glenmark Pharmaceuticals Ltd has informed BSE about the Shareholding Pattern as on June 30, 2014.08-07-2014
Glenmarks novel monoclonal antibody GBR 830 for treatment of autoimmune diseases entering human trials
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated July 03, 2014, titled "Glenmarks novel monoclonal antibody GBR 830 for treatment of autoimmune diseases entering human trials"03-07-2014
Fixes Book Closure for Dividend & AGM
Glenmark Pharmaceuticals Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from July 14, 2014 to July 25, 2014 (both days inclusive) for the purpose of Payment of Dividend & 36th Annual General Meeting (AGM) of the Company to be held on July 25, 2014.30-06-2014
Glenmark Pharmaceuticals inaugurates new Antibody Manufacturing Facility in La Chaux-de-Fonds, Switzerland
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated June 04, 2014 titled "Glenmark Pharmaceuticals inaugurates new Antibody Manufacturing Facility in La Chaux-de-Fonds, Switzerland"04-06-2014
Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Glenmark Pharmaceuticals Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 199228-05-2014
Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Glenmark Pharmaceuticals Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 199227-05-2014
Announces Q4 & FY14 results, Management Discussion & Analysis and Results Press Release for the period ended March 31, 2014
Glenmark Pharmaceuticals Ltd has announced the following results for the quarter & year ended March 31, 2014:The Audited results for the Quarter ended March 31, 2014The Company has posted a net profit of Rs. 1516.68 million for the quarter ended March 31, 2014 as compared to Rs. 849.19 million for the quarter ended March 31, 2013. Total Income has increased from Rs. 5117.93 million for the quarter ended March 31, 2013 to Rs. 6872.56 million for the quarter ended March 31, 2014....08-05-2014
Board recommends Dividend
Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 08, 2014, inter alia, has recommended Dividend @ 200% i.e. Rs. 2/- per share (face value Re. 1/-) on the Equity Share Capital of the Company for the financial year 2013-2014 subject to the approval of the Shareholders at the ensuing Annual General Meeting.08-05-2014